Trial IRCT20190727044343N1
Publication Davoodi L, Int J Clin Pract (2020) (published paper)
Dates: 2020-03-15 to 2020-03-27
Funding: Public/non profit (Mazandaran University of Medical Science, Sari, Iran)
Conflict of interest: No
Methods | |
RCT Blinding: double blinding | |
Location :
Single center / Iran Follow-up duration (days): 14 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
Febuxostat 80 mg orally once a day for 5 days |
|
Control
Hydroxychloroquine 200 mg orally twice a day for 5 days | |
Participants | |
Randomized participants : Febuxostat =30 Hydroxychloroquine=30 | |
Characteristics of participants N= 60 Mean age : NR 32 males Severity : Mild: n= 54/ Asymptomatic: n=0 Number of vaccinated participants: NR | |
Primary outcome | |
In the register CT-scan findings Before the intervention and 2 weeks after the intervention | |
In the report rate of hospitalization. | |
Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Yes |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Some concerns |
General comment | In addition to the published report, the trial registry was used in data extraction and assessment of risk of bias. The trial achieved is registered sample size, but was affected by 10% attrition. There were differences between the trial registry and the published report in primary outcome and inclusion/exclusion criteria. All participants were outpatients. Doses and schedules of the study drugs were not included in the trial registry. The registry specified the trial as 'double blind' however the report describes the study as 'open-label' study with blinded outcome assessors. |